Valuation: CSL Limited

Market Cap 41.24B 36.04B 33.26B 30.65B 57.78B 3,971B 59.06B 397B 156B 1,945B 155B 151B 6,696B P/E 2026 *
-46.2x
P/E 2027 * 28.7x
Enterprise Value 50.09B 43.77B 40.39B 37.23B 70.17B 4,823B 71.73B 483B 190B 2,362B 188B 184B 8,132B EV / Sales 2026 *
3.26x
EV / Sales 2027 * 3.16x
Free-Float
99.3%
Yield 2026 *
3.31%
Yield 2027 * 3.4%
1 day+1.54%
1 week+0.69%
Current month+8.47%
1 month+14.53%
3 months-12.22%
6 months-26.22%
Current year-24.44%
1 week 21.02
Extreme 21.0152
21.98
1 month 19.44
Extreme 19.44
22.54
Current year 16.01
Extreme 16.01
33.53
1 year 16.01
Extreme 16.01
44.86
3 years 16.01
Extreme 16.01
54.5
5 years 16.01
Extreme 16.01
58.62
10 years 16.01
Extreme 16.01
58.99
Manager TitleAgeSince
Chief Executive Officer 63 10/02/2026
Director of Finance/CFO 52 06/10/2025
Chief Operating Officer - 30/04/2025
Director TitleAgeSince
Director/Board Member 72 16/10/2018
Director/Board Member 70 01/02/2011
Director/Board Member 71 08/12/2019
Change 5-day change 1-year change 3-year change Capi.($)
+1.54%+0.69% - - 41.24B
-0.33%+1.83%+24.73%-6.86% 68.85B
+0.67%+0.93%+36.86%+197.49% 52.13B
+0.94%+39.60%+39.60%+39.60% 43.46B
-1.40%+3.43%+64.81%-25.41% 30.41B
-2.11%-9.45%+97.76%-49.58% 24.53B
+0.51%+0.46%+72.78%+90.09% 23.42B
-5.57%-0.84%-0.11%+182.38% 19.75B
-0.86%-1.99%+70.03%+117.01% 16.57B
+1.34%-5.25%+74.97%+150.25% 15.95B
Average -0.53%-1.43%+53.49%+77.22% 32.79B
Weighted average by Cap. -0.20%-0.41%+46.68%+66.43%

Financials

2026 *2027 *
Net sales 15.38B 13.44B 12.41B 11.43B 21.55B 1,481B 22.03B 148B 58.32B 726B 57.77B 56.51B 2,498B 15.62B 13.65B 12.59B 11.61B 21.88B 1,504B 22.37B 151B 59.21B 737B 58.65B 57.37B 2,536B
Net income -897M -784M -723M -667M -1.26B -86.4B -1.28B -8.65B -3.4B -42.32B -3.37B -3.3B -146B 1.18B 1.04B 955M 881M 1.66B 114B 1.7B 11.42B 4.49B 55.88B 4.45B 4.35B 192B
Net Debt 8.85B 7.73B 7.13B 6.58B 12.39B 852B 12.67B 85.27B 33.54B 417B 33.23B 32.5B 1,436B 8.06B 7.05B 6.5B 5.99B 11.3B 777B 11.55B 77.72B 30.57B 380B 30.28B 29.62B 1,309B
Logo CSL Limited
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.
Employees
29,904
Date Price Change Volume
17/07/26 US$21.76 +1.54% 161,857
16/07/26 US$21.43 -0.19% 250,265
15/07/26 US$21.47 -0.51% 347,942
14/07/26 US$21.58 +2.27% 428,819
13/07/26 US$21.10 -2.36% 300,631
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
86.11USD
Average target price
96.64USD
Spread / Average Target
+12.23%

Quarterly revenue - Rate of surprise